ScoreHaematology

Revised International Prognostic Scoring System for myelodysplastic syndromes (IPSS-R)

Classifies MDS into five risk groups by cytogenetics, blasts and depth of cytopenias, with optional age adjustment.

Updated 31 October 2026

When to use it

Adults with primary MDS at diagnosis, before disease-modifying therapy, to guide prognosis and treatment.

What it needs

  • Cytogenetic groupOptions: Very good: −Y, del(11q) · Good: normal, del(5q), del(12p), del(20q), double including del(5q) · Intermediate: del(7q), +8, +19, i(17q), any other single or double clones · Poor: −7, inv(3)/t(3q)/del(3q), double including −7/del(7q), complex with 3 abnormalities · Very poor: complex with > 3 abnormalities
  • Bone marrow blastsOptions: ≤ 2 % · > 2 % to < 5 % · 5–10 % · > 10 %
  • HaemoglobinOptions: ≥ 10 g/dL · 8 to < 10 g/dL · < 8 g/dL
  • PlateletsOptions: ≥ 100 × 10⁹/L · 50 to < 100 × 10⁹/L · < 50 × 10⁹/L
  • Absolute neutrophil countOptions: ≥ 0.8 × 10⁹/L · < 0.8 × 10⁹/L
  • Age (optional, for IPSS-RA) (optional)Units: años

The points for each answer and the automatic total are in the app.

How to interpret it

IPSS-R score
ResultInterpretation
< 2Very low (≤ 1.5): median survival ≈ 8.8 years
2 to < 3.5Low (> 1.5–3): median survival ≈ 5.3 years
3.5 to < 5Intermediate (> 3–4.5): median survival ≈ 3.0 years
5 to < 6.5High (> 4.5–6): median survival ≈ 1.6 years
≥ 6.5Very high (> 6): median survival ≈ 0.8 years

In the app it also calculates: IPSS-RA (age-adjusted, survival only).

Practical tip

Age adjustment (IPSS-RA) only changes the survival estimate, not the risk of AML transformation.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top